However , carnitine supplementation at dosages of ≤ 1000 mg/day ( p = 0.035 ) or equal to 2000 mg/day ( p = 0.013 ) result ed in significant reduction in ALT level , while doses more than 2000 mg/day did not change ALT  significantly .
Carnitine exerts its reducing effect on serum ALT and AST levels only when these aminotransferases are raised or when the duration of supplementation lasts at least 3 months .
Results of the current meta- analysis showed that carnitine supplementation can decrease serum AST and ALT levels significantly , especially when supplementation lasts 3 months or more in patients with elevated serum aminotransferase levels
Effect of Oral L-Carnitine Administration on Insulin Sensitivity and Lipid Profile in Type 2 Diabetes Mellitus Patients
Aim : It was the aim of this study to evaluate the effect of oral L-carnitine administration on insulin sensitivity and lipid profile in subjects with type 2 diabetes mellitus . Subjects and Methods : A r and omized , double-blind , placebo-controlled clinical trial was carried out in 12 subjects with type 2 diabetes . Six subjects received L-carnitine 1 g orally 3 times a day before meals for a period of 4 weeks . Six other individuals took a placebo for the same period of time , as the control group . Before and after the intervention , insulin sensitivity and the lipid profile were estimated . To assess insulin sensitivity , the euglycemic-hyperinsulinemic clamp technique was performed . Wilcoxon ’s signed rank and the Mann-Whitney U test were used for the statistical analyses . Results : There were no significant differences in basal clinical characteristics between the 2 groups . Insulin sensitivity and the basal lipid profile were similar . There were no significant changes in either group after the intervention in insulin sensitivity ( 3.2 ± 1.2 vs. 4.5 ± 1.7 mg/kg/min , p = 0.115 , and 3.5 ± 0.6 vs. 3.5 ± 0.4 mg/kg/min , p = 0.917 , for the placebo and L-carnitine groups , respectively ) and in lipid profile . Conclusion : L-Carnitine orally administered for a period of 4 weeks did not modify insulin sensitivity or the lipid profile
However , carnitine supplementation at dosages of ≤ 1000 mg/day ( p = 0.035 ) or equal to 2000 mg/day ( p = 0.013 ) result ed in significant reduction in ALT level , while doses more than 2000 mg/day did not change ALT  significantly .
Carnitine exerts its reducing effect on serum ALT and AST levels only when these aminotransferases are raised or when the duration of supplementation lasts at least 3 months .
Results of the current meta- analysis showed that carnitine supplementation can decrease serum AST and ALT levels significantly , especially when supplementation lasts 3 months or more in patients with elevated serum aminotransferase levels